Statins and Erectile Dysfunction

[1]  J. Kaminetsky.  Epidemiology and pathophysiology of male sexual dysfunction , 2008, International Journal of Impotence Research.

[2]  M. Lapeyre-Mestre,et al.  Prise en charge thérapeutique des patients diabétiques en France : Apport de la Banque Nationale de Pharmacovigilance , 2007 .

[3]  Benjamin S. Waxman,et al.  The effects of quinapril and atorvastatin on the responsiveness to sildenafil in men with erectile dysfunction , 2006, Vascular medicine.

[4]  S. Kimmel,et al.  ORIGINAL RESEARCH—ED PHARMACOTHERAPY: Can Atorvastatin Improve the Response to Sildenafil in Men with Erectile Dysfunction Not Initially Responsive to Sildenafil? Hypothesis and Pilot Trial Results , 2006 .

[5]  G. Jackson,et al.  Erectile dysfunction and statin treatment in high cardiovascular risk patients , 2006, International journal of clinical practice.

[6]  Frantz Thiessard,et al.  The history of disproportionality measures (reporting odds ratio, proportional reporting rates) in spontaneous reporting of adverse drug reactions , 2005, Pharmacoepidemiology and drug safety.

[7]  W. Campbell,et al.  Dermatomyositis‐like syndrome and HMG‐CoA reductase inhibitor (statin) intake , 2004, Muscle & nerve.

[8]  M. Lapeyre-Mestre,et al.  Upper gastrointestinal adverse drug reactions and cyclo-oxygenase-2 inhibitors (celecoxib and rofecoxib): a case/non-case study from the French Pharmacovigilance Database , 2004, European Journal of Clinical Pharmacology.

[9]  W. Diemont,et al.  Is decreased libido associated with the use of HMG-CoA-reductase inhibitors? , 2004, British journal of clinical pharmacology.

[10]  T. Walley,et al.  Variations and increase in use of statins across Europe: data from administrative databases , 2004, BMJ : British Medical Journal.

[11]  F. Haramburu,et al.  Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database. , 2003, British journal of clinical pharmacology.

[12]  J. Bermejo,et al.  Portable spectral Doppler echocardiographic device: overcoming limitations , 2003, Heart.

[13]  J. Hampson,et al.  Do lipid-lowering drugs cause erectile dysfunction? A systematic review. , 2002, Family practice.

[14]  S. Evans,et al.  Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports , 2001, Pharmacoepidemiology and drug safety.

[15]  R. Lewis,et al.  Epidemiology of erectile dysfunction. , 2000, The Urologic clinics of North America.

[16]  E. Brown,et al.  The Medical Dictionary for Regulatory Activities (MedDRA) , 1999, Drug safety.

[17]  A. Bate,et al.  A Bayesian neural network method for adverse drug reaction signal generation , 1998, European Journal of Clinical Pharmacology.

[18]  G. Jackson,et al.  Drug points: Simvastatin and impotence , 1997 .

[19]  I. Boyd.  Comment: HMG-CoA Reductase Inhibitor-Induced Impotence , 1996, The Annals of Pharmacotherapy.

[20]  P. Giral,et al.  Men treated with hypolipidaemic drugs complain more frequently of erectile dysfunction , 1996, Journal of clinical pharmacy and therapeutics.

[21]  M. Zini,et al.  Testicular function in hypercholesterolemic male patients during prolonged simvastatin treatment. , 1996, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[22]  I. Lossos,et al.  HMG-CoA Reductase Inhibitor-Induced Impotence , 1996, The Annals of pharmacotherapy.

[23]  N. Moore,et al.  [French pharmacovigilance database system: examples of utilisation]. , 1995, Therapie.

[24]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[25]  D. Capellà,et al.  Gemfibrozil-Induced Impotence , 1993, The Annals of pharmacotherapy.

[26]  A. Bharani,et al.  Sexual dysfunction after gemfibrozil. , 1992, BMJ.

[27]  D. Betteridge,et al.  Effects of pravastatin and cholestyramine on gonadal and adrenal steroid production in familial hypercholesterolaemia. , 1991, British journal of clinical pharmacology.

[28]  T. Benraad,et al.  The HMG-CoA reductase inhibitor simvastatin suppresses human testicular testosterone synthesis in vitro by a selective inhibitory effect on 17-ketosteroid-oxidoreductase enzyme activity , 1991, The Journal of Steroid Biochemistry and Molecular Biology.

[29]  J. Bargay,et al.  Gemfibrozil-induced impotence , 1990, The Lancet.

[30]  J. Schneider,et al.  Impotence in patients treated with clofibrate. , 1975, Atherosclerosis.

[31]  M. Lapeyre-Mestre,et al.  HMG CoA Reductase Inhibitors and Impotence , 2006, Drug safety.

[32]  M. Lindquist,et al.  A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions , 2002, Pharmacoepidemiology and drug safety.

[33]  J. Reynolds.  Martindale : the extra pharmacopoeia , 1993 .